{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ReSPECT-GBM","nct_id":"NCT01906385","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=respect-gbm-nct01906385. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Arm\n\nPhase I:\n\nExperimental: Dose Escalation for Cohorts 1-8 Each participant will receive a single administration of 186RNL. At each dose level, a minimum of three to a maximum of six participants will be enrolled.\n\nIf no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.\n\nThe dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below:\n\nCOHORT ACTIVITY Cohort 1 (1.0 mCi) Cohort 2 (2.0 mCi) Cohort 3 (4.0 mCi) Cohort 4 (8.0 mCi) Cohort 5 (13.4 mCi) Cohort 6 (22.3 mCi) Cohort 7 (31.2 mCi) Cohort 8 (41.5 mCi)\n\nPhase 2:\n\nSingle arm, prospective study utilizing a non-DLT dose obtained from the dose escalation portion of IND 116117, NIH-NCI Grant (22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL and 8.8 mL total volume).","label":"186Rhenium Liposome Treatment","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-04","type":"ESTIMATED"},"conditions":["Glioma"],"enrollment":{"count":55,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Rhenium Liposome Treatment","otherNames":["Rhenium-186 NanoLiposome"],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"Cerenome","official_title":"A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1: Maximum Tolerated Dose","timeFrame":"90 days"},{"measure":"Phase 2: Overall Survival","timeFrame":"12 Months"}],"references":[{"citation":"Wu C, Hormuth DA 2nd, Christenson CD, Woodall RT, Abdelmalik MRA, Phillips WT, Hughes TJR, Brenner AJ, Yankeelov TE. Image-guided patient-specific optimization of catheter placement for convection-enhanced nanoparticle delivery in recurrent glioblastoma. Comput Biol Med. 2024 Sep;179:108889. doi: 10.1016/j.compbiomed.2024.108889. Epub 2024 Jul 19.","pmid":"39032243","type":"DERIVED"}],"start_date":{"date":"2015-06-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","url":"https://clinicaltrials.gov/study/NCT01906385"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/respect-gbm-nct01906385"}